Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
By M. Kaufmann, G. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J. Blohmer, W. Eiermann, R. Jackesz, W. Jonat and 10 more. Journal of Clinical Oncology, 2006
719 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/de3cb12f98c54108861ba25770a759c4b88bd107
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, background): “Endocrine therapy without intent for surgery has typically been reserved for patients who are poor surgical candidates and medically unfit for chemotherapy.(99,100) In this context, ASCO’s geriatric assessment (GA) guideline has highlighted the importance of assessment of underlying health status fo”
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “A majority of the Panel considered that neoadjuvant cytotoxic therapy was of value beyond its role in facilitating conservative surgery and noted the improved prognostic information associated with pathological complete response to such therapy, particularly in patients with ‘HER2 positive’ and ‘Tri”
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Preoperative systemic therapy The primary objective of this therapy is to improve resectability and cosmesis [54].”
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012, result): “Pathologic complete response (pCR) has predicted long-term outcome in several neoadjuvant studies and is therefore a potential surrogate marker for survival.(2,3) However, selected trials comparing different neoadjuvant regimens have failed to demonstrate an association between pCR rate and improved”